Ghassan Abou-Alfa, MD – HIMALAYA Phase III trial – Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi.m4v Liver 3 Mins Read0 Dr. Ghassan Abu Alfa, MD with Memorial Sloan Kettering Cancer Center in New York, provides an update on the key…
